Zobrazeno 1 - 10
of 417
pro vyhledávání: '"Ji-Youn Han"'
Autor:
Ji-Youn Han, Myung-Ju Ahn, Ki Hyeong Lee, Yun-Gyoo Lee, Dong-Wan Kim, Young Joo Min, Sang-We Kim, Eun Kyung Cho, Joo-Hang Kim, Gyeong-Won Lee, Sung Sook Lee, Na Mi Lee, Hyun Woo Jang, Heewon Han, Hyejoo Park, Jieon Lee, Byoung Chul Cho
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-10 (2024)
Abstract Background Lazertinib is a potent, irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with significant efficacy in patients with EGFR T790M-mutated non-small cell lung cancer (NSCLC). This
Externí odkaz:
https://doaj.org/article/8bfcc4d65fa047f3a5990e84062ee6df
Autor:
Hyondeog Kim, Wonyeop Lee, Youngwook Kim, Sang-Jin Lee, Wonyoung Choi, Geon Kook Lee, Seung-Jin Park, Shinyeong Ju, Seon-Young Kim, Cheolju Lee, Ji-Youn Han
Publikováno v:
Experimental and Molecular Medicine, Vol 56, Iss 9, Pp 2082-2095 (2024)
Abstract Patients with lung adenocarcinoma who have never smoked (NSLA) and lack key driver mutations, such as those in the EGFR and ALK genes, face limited options for targeted therapies. They also tend to have poorer outcomes with immune checkpoint
Externí odkaz:
https://doaj.org/article/2cba0f79170d4894b1ae702c73614477
Autor:
Benjamin J. Solomon, M.B.B.S., PhD, Ibiayi Dagogo-Jack, MD, Se-Hoon Lee, MD, Michael J. Boyer, M.B.B.S., PhD, Suresh S. Ramalingam, MD, Enric Carcereny, MD, Enriqueta Felip, MD, PhD, Ji-Youn Han, MD, PhD, Toyoaki Hida, PhD, Brett G.M. Hughes, M.B.B.S., Sang-We Kim, MD, PhD, Makoto Nishio, MD, PhD, Takashi Seto, MD, Tatsuro Okamoto, MD, PhD, Xiaoxi Zhang, PhD, Jean-Francois Martini, PhD, Erjian Wang, MD, PhD, Steven De Beukelaer, MD, Todd M. Bauer, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 7, Pp 100685- (2024)
Introduction: The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in ALK-positive or ALK-negative advanced NSCLC, respectively. Methods: Starting d
Externí odkaz:
https://doaj.org/article/50d39c846b474baea88547c6b345e6aa
Autor:
Jiyun Lee, Hee Kyung Ahn, Sang‐We Kim, Ji‐Youn Han, Sung Sook Lee, Hyung Soon Park, Hyun Woo Lee, Joo‐Hang Kim, Eunhan Cho, Reto Huggenberger, Byoung Chul Cho
Publikováno v:
Cancer Medicine, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Objective KINDLE‐Korea is part of a real‐world KINDLE study that aimed to characterize the treatment patterns and clinical outcomes of patients with stage III non‐small cell lung cancer (NSCLC). Materials and Methods The KINDLE was an
Externí odkaz:
https://doaj.org/article/363f3894d7f34432b590291acb09d17c
Publikováno v:
Cancer Medicine, Vol 12, Iss 11, Pp 12285-12298 (2023)
Abstract Background Patterns of treatment failure and subsequent treatment in non‐small cell lung cancer (NSCLC) patients treated with osimertinib are scarcely known. We analyzed the disease progression during osimertinib treatment to identify pote
Externí odkaz:
https://doaj.org/article/8e9e14bb8bf445218d248217d89bd732
Autor:
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A. Shepherd, Krishna C. Bulusu, Gianluca Laus, Barbara Collins, J. Carl Barrett, Ryan J. Hartmaier, Vassiliki Papadimitrakopoulou
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-8 (2023)
In the phase III AURA3 study (NCT02151981), the third-generation epidermal growth factor receptor tyrosine kinase inhibitor osimertinib prolonged progression-free survival versus platinum-doublet chemotherapy in patients with EGFR T790M advanced NSCL
Externí odkaz:
https://doaj.org/article/97023c9e42e0450eab3688b9d4689761
Autor:
Kyubin Lee, Daejin Hyung, Soo Young Cho, Namhee Yu, Sewha Hong, Jihyun Kim, Sunshin Kim, Ji-Youn Han, Charny Park
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 21, Iss , Pp 1978-1988 (2023)
Alternative splicing (AS) events modulate certain pathways and phenotypic plasticity in cancer. Although previous studies have computationally analyzed splicing events, it is still a challenge to uncover biological functions induced by reliable AS ev
Externí odkaz:
https://doaj.org/article/7988cf259f9e41028a2b65a58e3b840b
Autor:
Namhee Yu, Mihwa Hwang, Youngjoo Lee, Bo Ram Song, Eun Hye Kang, Hanna Sim, Beung-Chul Ahn, Kum Hui Hwang, Jihyun Kim, Sehwa Hong, Sunshin Kim, Charny Park, Ji-Youn Han
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-16 (2023)
Abstract Background A pharmacogenomic platform using patient-derived cells (PDCs) was established to identify the underlying resistance mechanisms and tailored treatment for patients with advanced or refractory lung cancer. Methods Drug sensitivity s
Externí odkaz:
https://doaj.org/article/e32f18ba5a954e30a49113074dfb0ffc
Autor:
Seong Bok Jang, PhD, Kyeong Bae Kim, PhD, Sujin Sim, MS, Byoung Chul Cho, MD, PhD, Myung-Ju Ahn, MD, PhD, Ji-Youn Han, MD, PhD, Sang-We Kim, MD, PhD, Ki Hyeong Lee, MD, PhD, Eun Kyung Cho, MD, PhD, Nahor Haddish-Berhane, PhD, Jaydeep Mehta, PharmD, PhD, Se-Woong Oh, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 10, Pp 100224- (2021)
Introduction: Lazertinib is a potent, irreversible, brain-penetrant, mutant-selective, and wild-type–sparing third-generation EGFR tyrosine kinase inhibitor (TKI), creating a wide therapeutic index. Cardiovascular adverse events (AEs), including QT
Externí odkaz:
https://doaj.org/article/ff220c17e38940e2b6f3066799fe6c45
Publikováno v:
Clinical and Translational Medicine, Vol 11, Iss 9, Pp n/a-n/a (2021)
Externí odkaz:
https://doaj.org/article/3a2a706e71f04d019333066bff5c4768